Drugs / cePolytreg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05349591 | Aug 2022 → May 2025 | type 1 diabetes mellitus | University of Alberta | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cePolytreg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05349591 ↗ |
| Modality | Cell therapy | “Cryoperserved PolyTregs (cePolyTregs) is a new cellular therapeutic for allogeneic or autologous applications” NCT05349591 ↗ |
| Route | Intravenous | “The thawed cePolyTregs product will be administered via a peripheral intravenous (IV) line” NCT05349591 ↗ |